Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Luspatercept”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Testing effectiveness (Phase 2)Study completedNCT01749540
What this trial is testing

Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)

Who this might be right for
B-Thalassemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 64
Early research (Phase 1)Study completedNCT01432717
What this trial is testing

Study of ACE-536 in Healthy Postmenopausal Women

Who this might be right for
Anemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 40
Not applicableStudy completedNCT07073690
What this trial is testing

Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

Who this might be right for
Myelodysplastic Syndromes
Bristol-Myers Squibb 88
Not applicableStudy completedNCT05520749
What this trial is testing

Efficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi Mielodisplastiche

Who this might be right for
Myeloid Dysplasia
Fondazione Italiana Sindromi Mielodisplastiche-ETS 215
Testing effectiveness (Phase 2)Looking for participantsNCT04143724
What this trial is testing

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Who this might be right for
Beta-Thalassemia
Celgene 99
Not applicableActive Not RecruitingNCT06875219
What this trial is testing

To Evaluate Long- Term Safety and Efficacy of Luspatercept

Who this might be right for
Thalassemia Major
Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia 350
Testing effectiveness (Phase 2)Study completedNCT04477850
What this trial is testing

Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Who this might be right for
Myelodysplastic Syndromes
Celgene 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07450313
What this trial is testing

The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT

Who this might be right for
HSCT
Institute of Hematology & Blood Diseases Hospital, China 20
Not applicableLooking for participantsNCT07215975
What this trial is testing

A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

Who this might be right for
β-thalassemia
Bristol-Myers Squibb 200
Not applicableNot Yet RecruitingNCT06964971
What this trial is testing

Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study

Who this might be right for
Transfusion-dependent Non-severe Aplastic Anemia
The First Affiliated Hospital of Zhejiang Chinese Medical University 90
Post-approval studies (Phase 4)UnknownNCT06006949
What this trial is testing

Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Who this might be right for
Myelodysplastic Syndromes
Peking Union Medical College Hospital 62
Testing effectiveness (Phase 2)Study completedNCT02268409
What this trial is testing

Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)

Who this might be right for
β-Thalassemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 51
Testing effectiveness (Phase 2)Study completedNCT01749514
What this trial is testing

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

Who this might be right for
Anemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 116
Large-scale testing (Phase 3)Not Yet RecruitingNCT06927232
What this trial is testing

AZA+Lus VS AZA Monotherapy in HR-MDS

Who this might be right for
Higher-risk Myelodysplastic Syndrome
Peking Union Medical College Hospital 86
Not applicableEnded earlyNCT07681440
What this trial is testing

Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia

Who this might be right for
Myelodysplastic SyndromesBeta-thalassemia
Bristol-Myers Squibb 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07636486
What this trial is testing

Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies

Who this might be right for
LuspaterceptEpoetinPoor Erythroid Engraftment+1 more
Nanfang Hospital, Southern Medical University 90
Large-scale testing (Phase 3)Study completedNCT02631070
What this trial is testing

Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Celgene 229
Early research (Phase 1)Looking for participantsNCT06670222
What this trial is testing

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Low-risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 24
Large-scale testing (Phase 3)Active Not RecruitingNCT05949684
What this trial is testing

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

Who this might be right for
Myelodysplastic Syndromes
Bristol-Myers Squibb 402
Not applicableStudy completedNCT04973280
What this trial is testing

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Who this might be right for
Myelodysplastic SyndromesBeta-thalassemia
Celgene 187
Next Page